Abstract
FRI-335 - Loss of HbsAg is enough to discontinue long-term therapy with Nucleos(T)ide analogues in HbeAg negative CHB patients in real clinical practice?
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
